The cellular composition of the TME, the RNA gene expression profiling of T cells, aberrant chemokine and cytokine expression (i.e., CCL7, IL-33), and mutational tumor burden appear to play an important role in determining the efficacy of check point inhibitors-based immunotherapies50,51,60. This evidence concerns the gene IL33 and neoplasm.